In a proof-of-concept clinical trial, the oral treatment candidate zanubrutinib was shown to reduce disease activity for 10 people with hard-to-treat immunoglobulin G4-related disease (IgG4-RD) affecting the tear and salivary glands. Importantly, according to the researchers, zanubrutinib showed disease-controlling potential as a standalone therapy, bypassing the need for…
News
Valerio Therapeutics is teaming up with Abivax to discover new treatments for immune-mediated inflammatory diseases. The deal will provide funding to help advance Valerio’s internal pipeline, including a cell therapy candidate for IgG4‑related disease (IgG4‑RD), an immune-mediated inflammatory disease. “This collaboration brings together two highly complementary scientific…
A Phase 2 clinical trial Spero Therapeutics plans to start next year will test an investigational antibody-based therapy in people with immunoglobulin G4-related disease (IgG4-RD). Spero recently signed an exclusive license agreement with Innovent Biologics, the treatment’s original developer, that grants the company worldwide exclusive rights to develop, produce, and…
Cleveland Clinic specialists across multiple disciplines are working to speed the diagnosis of immunoglobulin G4-related disease (IgG4-RD), a rare and often-missed inflammatory condition. Their efforts include using artificial intelligence (AI) to develop a tool to help assess and manage the disease and create a patient registry. The specialists —…
Long-term use of the approved infusion therapy Uplizna (inebilizumab) leads to lasting cuts in flares, or periods of symptom worsening, in adults with active IgG4-related disease (IgG4-RD). That’s according to the first year of data from an open-label extension (OLE) portion of the Phase 3 MITIGATE clinical…
Glucocorticoid therapy alone is often not enough to manage rare cases of IgG4-related disease (IgG4-RD) that manifest with thickening of the membrane around the brain and recurrent blood clots blocking the brain’s blood vessels, according to a team of researchers in China who detailed the treatment of an older…
The investigational antibody therapy obexelimab lowered disease activity and reduced the need for glucocorticoid rescue therapy among people with immunoglobulin G4-related disease (IgG4-RD), according to final published data from a global clinical trial. The Phase 3 study, called INDIGO (NCT05662241), is the largest ever conducted in IgG4-RD,…
Zenas Biopharma has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of its experimental injection therapy, obexelimab, for immunoglobulin G4-related disease (IgG4-RD). “Our obexelimab [biologics license application] submission brings us one step closer to our goal of delivering this…
A new imaging technique shows promise for assessing disease activity and organ involvement in immunoglobulin G4-related disease (IgG4-RD). Compared with biopsy results, the [18F]FAPI PET/CT scan was 100% accurate in detecting lesions in various organs, including the lung, liver, muscles, pancreas, and kidney. The researchers developed a disease activity…
Zenas Biopharma says it’s on track to submit applications this year in the U.S. and the European Union seeking approval of its experimental injection therapy obexelimab for treating immunoglobulin G4-related disease (IgG4-RD). In fact, the developer noted that it intends to file a biologics license application to the…
